CLEC-2H Inhibitors
Chemical inhibitors of CLEC-2H target various signaling pathways that are crucial for its activation and function. Tyrphostin AG-1478, a tyrosine kinase inhibitor, directly impedes the activity of the EGFR kinase, an upstream regulator of CLEC-2H signaling, thereby preventing the downstream activation that would normally ensue. Similarly, Dasatinib and PP2, both Src family kinase inhibitors, can disrupt the phosphorylation events that are vital to downstream signaling involving CLEC-2H. The inhibition of these kinases by Dasatinib and PP2 can lead to a decrease in CLEC-2H mediated responses. LY294002 and Wortmannin, which are PI3K inhibitors, can halt the PI3K-Akt pathway, a crucial route for transmitting signals that could activate CLEC-2H. These inhibitors ensure that the activation of Akt is kept in check, which is a necessary step for several signaling processes within the cell.
Further along the signaling cascade, MEK inhibitors such as PD98059 and U0126 can impede the MAPK/ERK pathway. By blocking this pathway, these inhibitors can suppress the activation of signaling sequences that are essential for CLEC-2H function. SB203580 and SP600125 target other MAP kinase family members, namely p38 MAP kinase and JNK, respectively. SB203580's inhibition of p38 MAP kinase and SP600125's inhibition of JNK can interrupt the stress and cytokine signaling pathways that CLEC-2H may be part of. Y-27632, a ROCK inhibitor, acts on the Rho/ROCK pathway, which is known to intersect with CLEC-2H related pathways, suggesting that its inhibition can lead to reduced CLEC-2H activity. Lastly, Rapamycin, an mTOR inhibitor, can disrupt the PI3K/AKT/mTOR pathway, leading to a dampening of the signals that might otherwise enhance CLEC-2H activity. GF109203X, a PKC inhibitor, can also disrupt signaling pathways that involve CLEC-2H, ensuring that activation of PKC-dependent pathways is minimized, thereby reducing the functional activity of CLEC-2H.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tyrphostin AG 1478 | 175178-82-2 | sc-200613 sc-200613A | 5 mg 25 mg | $96.00 $421.00 | 16 | |
This tyrosine kinase inhibitor targets the EGFR kinase, which is upstream of CLEC-2H signaling. Tyrphostin AG-1478 inhibits EGF receptor autophosphorylation and activation, which could reduce the downstream activation of CLEC-2H as part of the signaling cascade. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor. Src kinases can be involved in the same pathways as CLEC-2H, thus inhibiting Src kinases can reduce the phosphorylation and activation of downstream molecules that may lead to the functional inhibition of CLEC-2H. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is another Src family kinase inhibitor. It inhibits Lck and Fyn, members of the Src kinase family, which could be part of the signaling cascade involving CLEC-2H, thus its inhibition could reduce CLEC-2H-mediated signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
This is a PI3K inhibitor, and by inhibiting PI3K, LY294002 can reduce Akt phosphorylation and downstream signaling, which might be necessary for the full activation of CLEC-2H signaling pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which is a part of the MAPK/ERK pathway. By inhibiting this pathway, PD98059 could prevent the activation of downstream signaling that may be necessary for CLEC-2H-mediated functions. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is also a MEK inhibitor, working similarly to PD98059, and could inhibit the MAPK/ERK pathway, potentially reducing the activation of pathways that involve CLEC-2H. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
This compound inhibits p38 MAP kinase, which could be involved in signaling pathways that are connected to CLEC-2H functions, thereby inhibiting the functional activity of CLEC-2H. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is involved in stress and cytokine signaling. By inhibiting JNK, this compound could interfere with signaling pathways that are required for CLEC-2H function. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a ROCK inhibitor. The Rho/ROCK pathway may intersect with pathways involving CLEC-2H, so inhibiting ROCK with Y-27632 could lead to inhibition of CLEC-2H activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor like LY294002, and by inhibiting PI3K it could reduce signaling through pathways that involve CLEC-2H, leading to its functional inhibition. | ||||||